जर्नल ऑफ़ प्रोटियोमिक्स और बायोइनफार्मेटिक्स
खुला एक्सेस

अमूर्त

Differential Proteomics Analysis of Oligodendrogliomas and Astrocytomas Using iTRAQ Quantification

Shi-de Lin, Jing-zhe Li, Peng Wang, Yu-jie Zang and Ting-bao Zhao

Background: Astrocytoma and oligodendroglioma are two histological subtypes of primary Central Nervous System (CNS) tumors. Because of the high cytoarchitectural variability and lacking accurate diagnosis biomarkers, distinguishing astrocytomas and oligodendrogliomas clinically remains challenging. Methods: The total protein lysates from of astrocytoma and oligodendroglioma clinical specimens were analyzed by 2DLC/MS/MS and quantified via Isobaric Tags Relative and Absolute Quantitation (iTRAQ). Differentially expressed proteins were further analyzed by Ingenuity Pathway Analysis (IPA) software. Lastly, potential bio-markers’ expression levels were validated by western blot. Results: A total 1856 proteins were identified. Among them, 83 proteins were increased and 82 proteins were decreased in astroglioma specimens compared to oligodendroglioma. Our bioinformatics study showed this protein profile change in astrocytoma more likely tend to enhance cell proliferation, migration and angiogenesis. Moreover, pathway-analysis showed that protein level of Rho Family GTPases pathway components was remarkably different between astrocytoma and oligodendroglioma. Lastly, two members of Rho family of GTPases, cell division control protein 42 homolog (CDC42) and transforming protein RhoA (RHOA) were found highly expressed in astrocytoma and oligodendroglioma, respectively. Discussion: Differential-proteomic analysis was validating to distinguish between astrocytomas and oligodendrogliomas. Two members of especially the Rho family of GTPases, CDC42 and RHOA, would be potential indicators to reflect the pathological characteristics of these two diseases.